NCT04336982 is a Phase 1 clinical trial of CC-90009 in Leukemia, Myeloid, Acute, sponsored by Celgene.

Who is sponsoring NCT04336982?

NCT04336982 is sponsored by Celgene.

What drugs are being tested in NCT04336982?

Interventions in NCT04336982: CC-90009, Venetoclax, Azacitidine, Gilteritinib.

What condition does NCT04336982 study?

NCT04336982 studies Leukemia, Myeloid, Acute.

Is NCT04336982 still recruiting?

NCT04336982 is currently terminated. Last updated 31 May 2024.

Last reviewed 2024-05-31 · How we verify

NCT04336982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Terminated Phase 1 Last updated 31 May 2024

What this trial tests

Phase 1 trial testing CC-90009 in Leukemia, Myeloid, Acute in 22 participants. Terminated before completion.

Timeline

5 August 2020

Primary endpoint
25 October 2023

5 April 2024

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	5 August 2020
Primary completion	25 October 2023
Estimated completion	5 April 2024
Sites	14 locations across France, Belgium, United Kingdom, Canada, United States

Drugs / interventions tested

CC-90009 — full drug profile →
Venetoclax (venetoclax) — full drug profile →
Azacitidine (azacitidine) — full drug profile →
Gilteritinib (GILTERITINIB) — full drug profile →

Conditions studied

Leukemia, Myeloid, Acute — all drugs for Leukemia, Myeloid, Acute →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Leukemia, Myeloid, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

PROTAC targeted protein degraders: the past is prologue.
Békés M, Langley DR, Crews CM. · · 2022 · cited 2098× · PMID 35042991 · DOI 10.1038/s41573-021-00371-6
Protein degraders enter the clinic - a new approach to cancer therapy.
Chirnomas D, Hornberger KR, Crews CM. · · 2023 · cited 430× · PMID 36781982 · DOI 10.1038/s41571-023-00736-3
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, et al · · 2024 · cited 195× · PMID 39048965 · DOI 10.1186/s12943-024-02046-3
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C, Jin L, Mbong N, Lu CC, et al · · 2021 · cited 178× · PMID 33197925 · DOI 10.1182/blood.2020008676
A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC, Agarwal S, Ahmad H, Amin K, et al · · 2022 · cited 137× · PMID 34774343 · DOI 10.1016/j.blre.2021.100905
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver NG, Maiti A, Kadia TM, Vyas P, et al · · 2022 · cited 126× · PMID 36218325 · DOI 10.1158/2159-8290.cd-22-0332
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.
Jan M, Sperling AS, Ebert BL. · · 2021 · cited 111× · PMID 33654306 · DOI 10.1038/s41571-021-00479-z

Verify or expand the search:

Other trials of CC-90009

Trials testing the same drug.

NCT04297124 — A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects · Phase 1 · completed
NCT02848001 — A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor · Phase 1 · terminated

Other recruiting trials for Leukemia, Myeloid, Acute

Currently open trials in the same condition.

NCT06852222 — A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke · Phase 3 · recruiting
NCT06651229 — A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
NCT06618001 — A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
NCT06643962 — Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearan · NA · recruiting
NCT06382168 — DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04336982 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 31 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04336982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing